Tag : HEPATOCELLULAR CARCINOMA

The debate highlighted the evolving role of combining locoregional and systemic therapy in intermediate-stage hepatocellular carcinoma (HCC), with potential to improve tumor response and facilitate conversion to curative treatment. However, concerns remain regarding toxicity, preservation of liver function, quality of life, and uncertain survival benefits, underscoring the importance of patient selection and individualized treatment.

EMERALD-3 demonstrated that STRIDE + lenvatinib + TACE significantly improved PFS compared with TACE alone in unresectable embolization-eligible hepatocellular carcinoma. The regimen also showed a favorable OS trend, improved tumor response, and a manageable safety profile, supporting its potential as a new treatment option.


Long-term data from the ASSURE study affirm that seladelpar, a first-in-class PPARδ agonist, provides sustained, clinically meaningful relief from cholestatic pruritus in PBC patients for up to 30 months. Findings show significant, durable improvements in numerical rating scale (NRS), 5-D Itch, and PBC-40 scores, transforming quality of life for symptomatic patients.

AASLD/IDSA recently published evidence-based practice recommendations, drawing on growing evidence of CHB prevention, surveillance, and treatment, to provide clear, practical guidance for health care professionals in optimizing care for individuals with CHB.

Multiple instance learning (MIL) applied to whole slide images (WSIs) was shown to improve the accuracy and consistency of hepatocellular carcinoma (HCC) histological differentiation. By capturing spatial and contextual tissue patterns, this artificial intelligence (AI) approach offers a scalable, standardized solution to support pathologists, streamline diagnostic workflows, and potentially improve clinical decision-making in HCC management.

MASLD drives persistent HCC risk despite HCV cure: Insights from a Japanese multicenter cohort study

The prospective ALTUS study found that a multi-target HCC blood test (mt-HBT) outperformed ultrasound in detecting early- and very early-stage hepatocellular carcinoma (HCC). By providing operator-independent and scalable surveillance, mt-HBT offers a promising alternative to imaging, with the potential to enhance early detection, adherence, and clinical outcomes in at-risk patients.

